tirzepatide protein tracking methods TrimRX Pharmacogenomics of Tirzepatide: Genomic Insights

Consultation Workflow: Train pharmacists to spend 510 minutes with every GLP-1 patient explaining medication timing, dosage escalation, and expected results

Tirzepatide, a dual GIP/GLP-1 receptor agonist approved by the FDA for diabetes management and chronic weight management, works by enhancing insulin secretion, suppressing glucagon, and reducing appetite

This higher protein intake helps preserve muscle mass during weight loss 2

Insulin secretion becomes more glucose-dependent rather than basal, reducing the risk of hypoglycemia while simultaneously improving postprandial glucose control

This is particularly relevant for people who were already well-controlled on antihypertensives before starting semaglutide, since weight loss itself tends to lower blood pressure, potentially creating an additive effect